Drug Profile
Malaria vaccine - Mymetics
Alternative Names: PEV 1002A; PEV 301; PEV 302; PEV3; PEV3ALatest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator Pevion Biotech
- Developer Mymetics Corporation; Swiss Tropical and Public Health Institute
- Class Antimalarials; Parasitic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Malaria
Highest Development Phases
- Suspended Malaria
Most Recent Events
- 20 Apr 2023 Suspended - Phase-I for Malaria (In adolescents, In children) in Tanzania (Parenteral)
- 20 Apr 2023 Suspended - Phase-I for Malaria in Switzerland (Parenteral)
- 28 Dec 2020 No recent reports of development identified for phase-I development in Malaria(In adolescents, In children) in Tanzania (Parenteral, Injection)